Skip to Main Content

Paper Details

Favipiravir for Treatment of Outpatients With Asymptomatic or Uncomplicated Coronavirus Disease 2019: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial.
Clin Infect Dis
26
2022
COVID-19, Coronavirus Disease, Favipiravir, PCRs, Participants, RNA-dependent RNA polymerase, SARS, SARS-CoV, SARS-CoV-2, coronavirus disease 2019, favipiravir, genome, participants, patients, severe acute respiratory syndrome coronavirus, severe acute respiratory syndrome coronavirus 2, women
Author NameAffiliation
Jason R AndrewsStanford University School of Medicine
Manisha DesaiStanford University
Manisha DesaiStanford University
  • 1 - 3

Datasets

Release 1.2